Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28050019 | 0.79 | P2RX7 (0.37) | EPHX2KCNH2ALDH1A1 | |
| SCHEMBL28049977 | 0.79 | P2RX7 (0.37) | EPHX2KCNH2ALDH1A1 | |
| SCHEMBL13387602 | 0.73 | CYSLTR2 (0.35) | ALDH1A1 | |
| SCHEMBL28863282 | 0.72 | LIPG (0.47) | — | |
| SCHEMBL27932102 | 0.72 | LIPG (0.47) | — | |
| SCHEMBL11119575 | 0.72 | MEN1 (0.40) | TLR8ALDH1A1 | |
| SCHEMBL5387664 | 0.71 | KDM4E (0.40) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL5397688 | 0.71 | KDM4E (0.40) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL5393198 | 0.71 | KDM4E (0.40) | KCNH2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL5380785 | 0.71 | KDM4E (0.40) | KCNH2KDM4EALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704468-B1 | Method for forming an extraction agent for the separation of actinides from lanthanides | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-04-27 | — | — | US | claimed |
| US-20100094042-A1 | METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC | 2010-04-15 | — | — | US | claimed |
| US-7704468-B1 | Method for forming an extraction agent for the separation of actinides from lanthanides | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100094042-A1 | METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100094042-A1 | METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100094042-A1 | METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2007037995-A2 | EXTRACTION AGENT AND METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094042-A1 | METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | GLA, PPIP5K2, DDOST | EPHX2 830/4885HSD11B1 2324/4885TLR8 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.